Your session is about to expire
← Back to Search
M7824 vs Pembrolizumab for Lung Cancer
Study Summary
This trial will compare the effectiveness of two drugs for treating patients with advanced lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 21 Patients • NCT04247282Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a strong allergic reaction to the study drugs M7824 or pembrolizumab.I can provide a recent (less than 6 months old) tumor tissue sample for testing.My nonsquamous NSCLC has a specific mutation (EGFR, ALK, ROS1, or BRAF V600E).I haven't had major surgery or high-dose chest radiation in the recent months.I have not had any cancer other than the one being studied in the last 3 years.I haven't had systemic therapy for my stage 4 NSCLC, but finished other treatments over 6 months ago with minimal side effects.You are expected to live for at least 3 more months.You have a disease that can be measured using a specific medical guideline called RECIST 1.1.My lung cancer is confirmed and advanced.My cancer has a high PD-L1 status.
- Group 1: M7824
- Group 2: Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What does the current research landscape look like for M7824?
"City of Hope first studied M7824 in 2010. So far, there have been 251 completed studies and 999 active trials. There is a significant presence of these trials in Rochester, New york."
What kind of side effects does M7824 have on patients?
"M7824's safety is based on extensive clinical data from Phase 3 trials, and it is estimated to be a 3 on a scale of 1 to 3."
Are there any available spots for patients who want to enroll in this trial?
"This particular trial is not searching for patients at this time, as the last update to the study was on July 4th, 2022. However, there are 1984 trials for patients with carcinoma, non-small-cell lung and 999 trials for M7824 that are currently enrolling participants."
What are the approved indications for M7824?
"M7824 is most frequently used to treat malignant neoplasms, but it can also be used to treat unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
How many people can enroll in this trial at most?
"This study has completed recruitment and is no longer looking for participants. The trial was first posted on 2018-10-01 and was most recently updated on 2022-07-04. However, there are presently 1984 studies actively enrolling participants with carcinoma, non-small-cell lung and 999 trials for M7824 actively searching for participants."
Share this study with friends
Copy Link
Messenger